tradingkey.logo

Lilly To Acquire Verve Therapeutics To Advance One-Time Treatments For People With High Cardiovascular Risk

ReutersJun 17, 2025 11:33 AM

- Verve Therapeutics Inc VERV.O:

  • LILLY TO ACQUIRE VERVE THERAPEUTICS TO ADVANCE ONE-TIME TREATMENTS FOR PEOPLE WITH HIGH CARDIOVASCULAR RISK

  • ELI LILLY - PROPOSED DEAL FOR PURCHASE PRICE OF $10.50 PER SHARE IN CASH

  • ELI LILLY - PROPOSED DEAL FOR A TOTAL POTENTIAL CONSIDERATION OF UP TO $13.50 PER SHARE IN CASH WITHOUT INTEREST

  • ELI LILLY - TRANSACTION IS NOT SUBJECT TO ANY FINANCING CONDITION

  • ELI LILLY: CVR HOLDERS WOULD BE ENTITLED TO GET CONTINGENT PAYMENT UPON FIRST PATIENT BEING DOSED WITH VERVE-102 FOR ASCVD IN U.S. PHASE 3 TRIAL

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI